(Recasts, adds details, dateline)
NEW YORK Jan 9 Barr Pharmaceuticals Inc
BRL.N said on Wednesday it has asked U.S. regulators to
approve its generic form of French drugmaker Sanofi-Aventis'
(SASY.PA) blockbuster Eloxatin treatment for colon cancer.
Barr said Sanofi-Aventis and its partner, privately held
Swiss drugmaker Debiopharm S.A., in turn, last week filed suit
in New Jersey federal court to prevent Barr from taking its
generic to market.
Eloxatin, which is given by injection, is used to treat
stage III colon cancer patients who have undergone complete
removal of their primary tumor, and to also treat advanced
cancer of the colon or rectum.
It had U.S. sales of about $1.1 billion during the
12-months ended October 2007, Barr said.
(Reporting by Ransdell Pierson, additional reporting by
Supantha Mukherjee in Bangalore; Editing by Tim Dobbyn)